EZZ Life Science Holdings Limited

EZZ

EZZ Life Science Holdings Ltd. engages in wholesale distributor of skin care products under the EAORON brand to pharmacies, supermarkets and specialist retailers. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-03-03. The firm is engaged in research and development in genomics and precision nutrition with a focus on four human health challenges, including genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company formulates, produces, markets and distributes health supplements under the brand of EZZ to retailers and consumers domestically and internationally. The firm is also a wholesale distributor of skin care products under the EAORON brand in Australia and New Zealand to pharmacies, supermarkets and specialist retailers. Its products under the EZZ brand include EZZ Hair Growth Spray, EZZ Hair Scrub, EZZ Hair Mask, EZZ Anti-frizz Hair Spray, EZZ Biotic Engastro Capsule, EZZ Coffee Jelly and EZZ Iron Jelly. The EZZ products cover market segments, including vitamin and dietary supplements, sports nutrition, herbal/ traditional and pediatric consumer health products.

F100

F100.AX was created on 2019-07-12 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to track the price and income performance of the FTSE 100 Index (before fees and expenses). The Index provides exposure to the largest 100 comoanies traded on the London Stock Exchange, based on their market capitalisation.

Elixir Energy Limited

EXR

Elixir Energy Ltd. engages in the exploration of oil and gas. The company is headquartered in Adelaide, South Australia. The company went IPO on 2004-07-19. The firm is primarily focused on coal bed methane (CBM) exploration and development in Mongolia, and tight gas appraisal in Queensland and green hydrogen production in Mongolia. The Company’s segments include Oil And Gas Exploration in Australia, Mongolia, the United States of America (USA); Clean Energy in Mongolia; and Solar Project in Mongolia. The firm has a 100% interest in the Nomgon IX CBM production sharing contract (PSC), located proximate to the Chinese border in Mongolia's South Gobi region. The Nomgon Project is located on the Mongolian Chinese border, around 400 kilometers (km) north of China's main gas transmission grid. The Nomgon Project license area covers approximately 30,000 square kilometers. The company also focuses on the green hydrogen production project, Gobi H2 in the South of Mongolia. Its subsidiaries include Golden Horde Pty Ltd, GOH LLC, GOH Clean Energy LLC, among others.

Nova EYE Medical Limited

EYE

Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia. The Company’s principal activities include the design, development, manufacture, marketing, sale, and distribution of surgical devices for the treatment of glaucoma, a cause of blindness. The firm is also engaged in the commercialization of its ophthalmic laser, 2RT. The Company’s segments include AlphaRET and Glaucoma surgical devices. The firm's AlphaRET segment has 2RT, which is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD). 2RT is a patented nano-pause laser device that rejuvenates retinal structures compromised by AMD. The Glaucoma Surgical Devices segment includes the design, manufacture, marketing and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. The firm's manufacturing facilities are located in Fremont, California, and Dunedin, New Zealand.